QLY Biotech Group Corp. [Rocket]

In millions, except per share items	Feb-28-23	Nov-30-22	Aug-31-22	May-31-22	Feb-28-22	Nov-30-21	Aug-31-21	May-31-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Revenue growth			-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross margin							65.0%
Selling, general and administrative [+]	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
General and administrative	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other operating expenses							0.0
EBITDA [+]			0.0	0.0			0.0	0.0
EBITDA growth	562.1%	117.7%	-389.8%	111.3%	-92.5%	-51.3%	-122.7%	13.4%
EBITDA margin							52.8%
Depreciation			0.0	0.0			0.0	0.0
EBITA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITA margin							54.9%
Amortization of intangibles			0.0	0.0			0.0	0.0
EBIT [+]	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT growth	562.1%	117.7%	-242.5%	84.6%	-92.6%	-53.6%	-134.9%	9.9%
EBIT margin							84.9%
Other income (expense), net							0.0
Pre-tax income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net margin							14.9%

Basic EPS [+]	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Growth	562.1%	117.7%	-910.7%	84.6%	-92.6%	-7.2%	-126.0%	-15.4%
Diluted EPS [+]	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Growth	562.1%	117.7%	-910.7%	84.6%	-92.6%	-7.2%	-126.0%	-15.4%

Shares outstanding (basic) [+]	3.9	3.9	3.9	3.9	3.9	3.9	3.9	3.9
Growth	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	27.6%	29.8%
Shares outstanding (diluted) [+]	3.9	3.9	3.9	3.9	3.9	3.9	3.9	3.9
Growth	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	27.6%	29.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.